Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo.
about
Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growthIsolation and characterization of a prenylcysteine lyase from bovine brainPrenylation of Rab8 GTPase by type I and type II geranylgeranyl transferasesInhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndromeRefinement and prediction of protein prenylation motifsHuman isoprenoid synthase enzymes as therapeutic targetsActivated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated ProteinsFarnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubulesInteraction of farnesylated PRL-2, a protein-tyrosine phosphatase, with the beta-subunit of geranylgeranyltransferase IIThematic review series: lipid posttranslational modifications. Fighting parasitic disease by blocking protein farnesylationBRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implicationsCombination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G(1)-S transition in Ki-Ras-overexpressing transformed adrenocortical cellsRas history: The saga continues.A novel role of farnesylation in targeting a mitotic checkpoint protein, human Spindly, to kinetochoresThe farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells.Proteomic analysis of bovine brain G protein gamma subunit processing heterogeneity.Amide-substituted farnesylcysteine analogs as inhibitors of human isoprenylcysteine carboxyl methyltransferase.Identification of novel peptide substrates for protein farnesyltransferase reveals two substrate classes with distinct sequence selectivities.Synthesis and screening of a CaaL peptide library versus FTase reveals a surprising number of substratesNiche-based screening identifies small-molecule inhibitors of leukemia stem cellsDifferential requirement of CAAX-mediated posttranslational processing for Rheb localization and signalingTargeting protein prenylation for cancer therapyTargeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer.p21(WAF1/CIP1) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor beta- and Sp1-responsive element: involvement of the small GTPase rhoA.Farnesyltransferase inhibitors. Preclinical development.A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.Combinatorial modulation of protein prenylationFarnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues.Amide-modified prenylcysteine based Icmt inhibitors: Structure-activity relationships, kinetic analysis and cellular characterizationFarnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.Novel Ras antagonist blocks human melanoma growth.Inhibiting signal transduction: recent advances in the development of receptor tyrosine kinase and Ras inhibitors.Murine guanylate-binding protein: incomplete geranylgeranyl isoprenoid modification of an interferon-gamma-inducible guanosine triphosphate-binding proteinFarnesyltransferase inhibitors in breast cancer therapy.Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cellsFarnesyl transferase inhibitors in the treatment of breast cancer.Drugging the undruggable RAS: Mission possible?Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.Pleiotropic functions of Rho GTPase signaling: a Trojan horse or Achilles' heel for breast cancer treatment?
P2860
Q24294230-AEB2E661-1032-4868-9336-FA99741BB687Q24310310-E51EAEC3-CF6F-426D-9A82-F5C631EF87CDQ24531139-4FB355A4-1F2F-4A9C-A0DD-FA2798D454DCQ24531946-856C3C52-93F8-4BCD-9C28-0601836B144AQ24812543-48482485-DC69-4FF0-B2F9-DB8215EC72F5Q26822639-DCD43ABE-9708-4E1B-B31D-9E32C28D3E11Q27027458-4FFB7590-00EE-4118-B82B-51A8CB6E4729Q28138265-DF5B7D5B-2A01-4A50-A1FE-953F08E3A86EQ28205756-3D44DA56-F323-4C20-BC3D-945A29F49893Q28285888-3BF77E02-9BA8-4556-98D2-799BA7CDD4D2Q28543370-48ED5924-8D6C-4CFF-A2D2-44CF252A686EQ28567838-6715448A-5972-4E85-A1FE-DA2BC7F29098Q30404024-0CC13C3D-4B93-44E0-AFA3-8822684412BFQ30635394-04DB953A-A4D0-4DE7-BF90-D9F091FF03EFQ31820996-035EE75C-09D3-43D0-A18A-1029A5047B97Q33228701-60986F48-E015-472D-9464-1F63F45DF76AQ33246884-468F2C4A-1B1A-4365-8B2D-71C9F3A96959Q33514156-18B68B2C-2BE7-41F0-B069-2B253ECA74ABQ33518159-BC905C50-460F-4E61-A09F-278249057C0BQ33563509-FF289DEB-1CB9-4CDB-B8E8-EC3E2EC78B95Q33604076-A34BCD44-2A3E-45B7-8EBF-8384AF4539F7Q33679239-359D2C92-7930-4018-8817-7E7A29F02440Q33779007-A8EA625A-D48A-459C-90D1-ED2CDE3DB79BQ33781631-4F4A3D5D-A7E8-4FD6-8436-19640BF5BF91Q33833364-10C09E7A-087D-455D-80CC-9DF3F454828EQ33914284-3721262A-0631-472C-A4EA-C61A41534170Q34071002-C0B12943-598D-46EF-9EBA-98DAA68A412CQ34090957-37F57D03-9090-480F-B196-826C66327F22Q34091952-4D2207EF-FD97-441E-961A-DC21F0442F2FQ34293555-56BE2A74-0B0F-472C-AA3C-478A1372A7F3Q34505870-9ADB2DDF-0483-467B-8F38-B8447F07DDC6Q34651534-87411FB8-53E9-434E-9757-4CDCA5C0B49EQ34728624-912B2720-5942-45EB-A665-C3E547DCEAB2Q35004480-BFD969B4-CA41-46F6-859C-3F59965C345EQ35043887-DCA3ACCD-42C5-4951-9F2D-FD7717643BE4Q35073354-F4BCC15E-9CD5-479B-8AAA-E575C23981D1Q35163434-6FE9DE78-B913-4D45-A0D1-F44B1CCE98E0Q35166852-0E193C8B-F9C9-4784-A79F-BB7D5900D328Q35186888-3E4928FF-25DF-4F05-84F5-CEDA32295DC6Q35287780-7E3A031F-C169-4EB4-AF00-B76829582185
P2860
Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo.
@en
Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo.
@nl
type
label
Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo.
@en
Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo.
@nl
prefLabel
Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo.
@en
Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo.
@nl
P2093
P2860
P356
P1476
Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo.
@en
P2093
P2860
P304
14093-14097
P356
10.1074/JBC.272.22.14093
P407
P577
1997-05-01T00:00:00Z